Home / Markets / Industries / Health Care
Thursday, September 25, 2008
Dragon to Present at BioContact Quebec 2008
Comtex
VANCOUVER, Sept 25, 2008 /PRNewswire-FirstCall via COMTEX/ ----Dragon Pharmaceutical Inc. ("Dragon Pharma" or the "Company" TSX: DDD; OTCBB: DRUG; BBSE: DRP), a leading international pharmaceutical company, today announced that Ms. Maggie Deng, Chief Operating Officer and Mr. Garry Wong, Chief Financial Officer will present at 9:30 a.m. ET on Friday, October 3, 2008 at BioContact Quebec 2008 at the Chateau Frontenac hotel in Quebec City, Canada.
Ms. Maggie Deng and Mr. Garry Wong will present Dragon Pharma's business overview including product lines, competitive strengths, and key growth strategies.
BioContact Quebec 2008 is a biopharmaceutical partnership symposium that brings together over 1,200 participants from biopharmaceutical companies to present various sectors and disciplines of their companies. The conference will be held on October 1-3, for more information about the conference, please visit http://www.biocontact.qc.ca/english/default.html.
About Dragon Pharmaceutical Inc.
Dragon Pharmaceutical, headquartered in Vancouver, Canada, is a leading manufacturer and distributor of a broad line of high-quality antibiotic products including 7-ACA, a key intermediate to produce cephalosporin antibiotics, clavulanic acid, and formulated cephalosporin antibiotic drugs. Dragon is the third largest 7-ACA producer and the first manufacturer and market leader of clavulanic acid products in China. Dragon utilizes its nationwide sales distribution network, close customer relationships, understanding of local markets and customer needs and low cost structure to outperform its international and domestic peers. With an annual capacity of 780 tons, Dragon is the largest exporter of 7-ACA in China. To learn more about Dragon Pharmaceutical Inc., please visit www.dragonpharma.com.
SOURCE Dragon Pharmaceutical Inc.
Copyright (C) 2008 PR Newswire. All rights reserved
FOX Translator
No data currently available.
No data currently available.
Some mutual funds want you to pay for the privilege of them (or your investment adviser) taking your money to invest. It's called a load, and it works like a cover charge to get into a nightclub. Luckily, there are such things as no-load funds. As the name implies, shares of these funds are sold without a fee paid to a broker or investment advisor.
The entire amount you invest in no-load funds goes to work for your returns. On the other hand, with load funds, right off the bat you're charged commission (not to mention other fees incurred over the life of the investment). Let's say, for example, you invest $25,000 into a load fund that charges a 5% commission. This costs you $1,250 off the top, bringing your actual investment down to only $23,750.
The often-cited horse race analogy argues against investing in load funds. Here's the logic behind it: Would you place a bet on a horse that had to start a race 200 yards behind the others? Well, maybe you would if you got a tip from a sketchy, trench coat-clad man in a dark alley. However, under most circumstances, it's not smart to put your money on that handicapped horse.
But some argue that at times that man in the trench coat (aka your broker) knows more about the horses than you do, and has a better shot at picking a winner. Also, sometimes these fees are unavoidable because some funds are available only through investment advisers.
Cost-benefit analysis can help determine when a load fund is worth it (in other words, when it will score you a load) and when it is better to "do it yourself" and avoid the fees. Load-fund fees range depending on share class and can cover a variety of costs, such as paper work and fund management.
